Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6).

Correa-Silva SR, Nascif SO, Molica P, Sá LB, Vieira JG, Lengyel AM

Clinical endocrinology29 Apr 2009Cited by 7 (Europe PMC)

PMID19453623DOI10.1111/j.1365-2265.2009.03618.xPepBankPUB-19453623

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01HumanNot a test of GHRP-6 aloneNon-randomized trialMechanism
In patients with Cushing's disease, GHRP‑6-stimulated peak cortisol fell after 3 and 6 months of ketoconazole treatment.
In plain wordsIn people with Cushing's disease, the cortisol rise after a GHRP‑6 test was lower after ketoconazole treatment.
Peptide
GHRP-6
Outcome
DecreaseGHRP-6-stimulated peak cortisol after ketoconazole
Study
n = 8
Comparator
Before ketoconazole
Outcome group
Stress hormones · Endocrine and hormones
Measurements
Peak cortisol after GHRP-6
1045.7 nmol/l
before ketoconazole
Peak cortisol after GHRP-6
767 nmol/l
3rd month
Peak cortisol after GHRP-6
571.1 nmol/l
6th month
Source sentences
Summary
The same was observed with basal serum cortisol (before: 612.5 +/- 69.0 nmol/l; 3rd month: 463.5 +/- 44.1; 6th month: 402.8 +/- 44.1) and ghrelin- and GHRP-6-stimulated peak cortisol levels (before: 1183.6 +/- 137.9 and 1045.7 +/- 132.4; 3rd month: 637.3 +/- 69.0 and 767.0 +/- 91.0; 6th month: 689.8…
1 context sentence(design, population, supporting numbers)
Summary · context
Eight untreated patients with CD (BMI: 28.5 +/- 0.8 kg/m(2)) were evaluated before and after 3 and 6 months of ketoconazole treatment and compared with 11 controls (BMI: 25.0 +/- 0.8).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1945362301
02HumanNot a test of GHRP-6 aloneNon-randomized trialMechanism
In patients with Cushing's disease, GHRP‑6-induced ACTH release increased after 6 months of ketoconazole treatment, but not significantly.
In plain wordsIn people with Cushing's disease, the ACTH rise after a GHRP‑6 test was higher after 6 months of ketoconazole, but the change was not significant.
Peptide
GHRP-6
Outcome
No significant changeGHRP-6-induced peak ACTH after ketoconazole
Study
n = 8
Comparator
Before ketoconazole
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
GHRP-6-induced ACTH release also increased (before: 60.7 +/- 17.2; 6th month: 78.5 +/- 12.1), although not significantly.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight untreated patients with CD (BMI: 28.5 +/- 0.8 kg/m(2)) were evaluated before and after 3 and 6 months of ketoconazole treatment and compared with 11 controls (BMI: 25.0 +/- 0.8).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1945362302

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.